Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
266. |
ECCT/20/06/09 | HIV-CORE 006 A Phase 1 Trial of ChAdOx1- and MVA-vectored Conserved Mosaic HIV-1 Vaccines in Healthy, Adult HIV-1-negative Volunteers in Eastern and Southern Africa |
Principal Investigator(s) 1. Professor Walter Jaoko, Jaoko, Site(s) in Kenya 1. KAVI-Institute of Clinical Research (Nairobi City county) 2. KEMRI/ Wellcome Trust Research Programme (Kilifi county) |
View |
267. |
ECCT/20/09/05 | THE ELLAVI UBT STUDY An investigation into the barriers and facilitators of scaling up the innovative, low-cost Ellavi Uterine Balloon Tamponade for postpartum hemorrhage in Kenya |
Principal Investigator(s) 1. Zahida P Qureshi 2. Omondi Ogutu 3. Alfred Onyango Osoti 4. George Nyakundi Gwako 5. James Soki 6. James Gitonga Site(s) in Kenya 1. Kenyatta National Hospital (Nairobi City county) 2. Mbagathi Hospital (Nairobi City county) 3. St. Marys Mission Hospital (Nairobi City county) |
View |
268. |
ECCT/20/07/03 | STAND A Phase III multicenter, randomized, double blind study to assess efficacy and safety of two doses of crizanlizumab verses placebo, with or without hydroxyurea/hydroxycarbamide therapy in adolescent and adult sickle cell disease patients with Vaso-Occlusive Crises (STAND) |
Principal Investigator(s) 1. Bernhards Ragama Ogutu Site(s) in Kenya 1. CREATES Strathmore University (Nairobi City county) 2. Getrudes Childrens Hospital (Nairobi City county) 3. International Cancer Institute (Elgeyo/Marakwet county) |
View |
269. |
ECCT/20/05/02 | COPCOV Chloroquine/ hydroxychloroquine prevention of coronavirus disease (COVID-19) in the healthcare setting; a randomised, placebo-controlled prophylaxis study (COPCOV) |
Principal Investigator(s) 1. Anthony Oliwa Etyang Site(s) in Kenya 1. KEMRI - Centre for Geographic Medicine Research Coast (CGMRC) (Kilifi county) 2. KEMRI-Centre for Global Health Research (CGHR) (Kisumu county) |
View |
270. |
ECCT/20/05/01 | ChAdOx1 nCoV-19 trial A phase Ib/II single-blinded, randomised, controlled study to determine safety, immunogenicity and efficacy of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19 in adults in Kenya |
Principal Investigator(s) 1. George Warimwe Site(s) in Kenya KEMRI-CGMRC |
View |